Skip to main content
PLOS Global Public Health logoLink to PLOS Global Public Health
. 2022 Nov 8;2(11):e0000486. doi: 10.1371/journal.pgph.0000486

A qualitative analysis of the COVID-19 vaccination rollout in Lagos, Nigeria: Client and provider perspectives on the plan, the process and the progress

Oluchi Kanma-Okafor 1,*,#, Yetunde Odusolu 2,#, Akin Abayomi 3,, Faisal Shuaib 4,, Moji Adeyeye 5,, Ibrahim Mustapha 6,, Segun Ogboye 3,, Dayo Lajide 3,, Hussein Abdur-Razzaq 3,, Ukamaka Okafor 7,, Uchenna Elemuwa 5,, Akin Osibogun 1,2,6,#
Editor: Sabine Hermans8
PMCID: PMC10021997  PMID: 36962511

Abstract

Mass vaccination has proven useful in the control of COVID-19, though vaccine rollout has met major challenges. The learning curve of this process has been valuable. This qualitative study aimed to assess the plan, the process and the progress of the COVID-19 vaccination rollout in Lagos, Nigeria. This study was conducted at vaccination centers in eight of the 20 Local Government Areas in Lagos State from May to July 2021 among healthcare administrators, health workers and vaccine recipients. Data were collected by conducting three key informant interviews, 24 in-depth interviews and eight focus group discussions to explore the vaccination experiences of participants and the challenges facing the vaccination plan and process. The interviews and discussions were recorded, transcribed verbatim and analyzed using the thematic approach. The four-phased plan for the vaccine rollout was clear to all the key informants because the vaccination process was preceded by training. The process was strengthened by the electronic registration system, though riddled by the frequently unstable electronic and internet data capturing. This was mitigated by a stopgap manual registration and recording of client details. Challenges in the logistics of maintaining supplies of the disposable materials required for the vaccination process were overcome by the creativity of the health professionals. Vaccine hesitancy, fueled by misinformation, myths and misconceptions about the vaccine and its side effects, played a huge role in the community response. The reported vaccine side effects were mild; fever, headaches, pain at the injection site, excessive eating and sleepiness. Though the COVID-19 vaccination process appeared to have largely made progress, the future of vaccination in Nigeria is predicated upon a bottom-up approach to programmatic planning, health education and local vaccine production. Collaborations such as public-private partnerships have the potential of boosting vaccine provision for Nigeria’s large population to ensure equitable access to vaccines.

Introduction

The coronavirus pandemic since its onset in 2019 has seen efforts the world over towards its control, including the production of vaccines. Successful vaccine rollout would interrupt the natural spread of the virus and lead to an end to the COVID-19 pandemic. The global effort toward COVID-19 vaccination has been monumental, shattering the past records of the fastest vaccine project of four and a half years (1963–1967) for the mumps vaccine [1]. The first mass vaccination programme started in the UK in early December 2020 and since then, the number of doses of the vaccine available globally for administration has gradually improved. At the time of writing, the number of doses of the COVID-19 vaccines secured globally was given as 17.5 billion [2]. The careful process of facilitating the vaccination response against COVID-19 included carefully examining the data available from many parts of the world about the vaccine. This was necessitated by the reports that the use of the AstraZeneca vaccine had been interrupted in many countries, mostly in Europe, as a precautionary measure because some recipients of the vaccine were said to have experienced blood clots as a side effect [3]. However, these reports about the formation of blood clots in recipients of the vaccine have since been proven to be false [4,5]. Vaccination against COVID-19 has been slow in Africa especially for the countries relying on doses from the COVAX initiative, a partnership between The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, The United Nations Children’s Fund (UNICEF) and The World Health Organisation (WHO) and from India where the local demand is being prioritized. Of the 1.3 billion COVID-19 vaccine doses administered globally, Africa currently has received only 1% [6]. Africa faces the overwhelming threat of being left behind as the proportions of the global COVID-19 vaccine doses received in Africa seem to be reducing [6].

While some countries in Africa like Botswana, Ethiopia and Ghana have had exemplary COVID-19 vaccine rollouts, some countries have administered less than half of the doses they have received [7]. Delays in the complete rollout and administration of vaccines have been attributed to factors such as inadequately trained personnel, a lack of funds to support the vaccination programme, poor planning and vaccine hesitancy based on myths and misinformation [6], although the apparently slow rollouts may be due to incorrect reporting.

In early March 2021, Nigeria received close to 4 million doses of the AstraZeneca/Oxford vaccine, COVID-19 vaccine manufactured by the Serum Institute of India (SII), through the COVAX facility, the vaccine coordinating arm of the Access to COVID-19 Tools (ACT) Accelerator [8]. The ACT Accelerator is an innovative collaboration working globally to ensure the speedy development and production of COVID-19 tests, treatments, and vaccines and their equitable accessibility to countries all over the world [9]. To enable the commencement of the COVID-19 vaccination in Nigeria, the vaccines were subsequently distributed to all the 36 States of the federation and the Federal Capital Territory [10]. To aid vaccine rollout IT systems were deployed, including vaccine-tracking systems (such as CDC’s VTrckS) and uniquely designed immunization information systems (IIS), necessary for allocating, distributing, recording, and monitoring the vaccines as they are distributed to various parts of the state. These posed an additional challenge in terms of operation and cybersecurity bearing in mind the sensitive nature of the patient data, to ensure privacy is protected. Some COVID-19-vaccine developers and regulators have already fallen victim to cyberattacks [11,12].

The Coronavirus vaccination campaign in Lagos State, Nigeria began on the 12th of March 2021 after receiving over 500,000 doses of the AstraZeneca vaccine, ten days after the vaccines provided for use in Nigeria were available for distribution to the States [13]. Vaccines were distributed to the Local Government Areas. Vaccine distribution was stratified according to the population of each Local Government Area. The vaccination process was based on a four-phase plan that recognised priority groups and the use of the T.E.A.C.H strategy for the COVID-19 vaccination plan [14,15]. T.E.A.C.H is an acronym for a five-point strategy used for the implementation of vaccination, where T stands for Traditional method of vaccinating target populations using desk review of available data sources, identifying the vaccination sites and rolling out, E stands for Electronic self-registration for health workers and the public using an internet link which provides an online form, A stands for Assisted electronic registration, C stands for Concomitant e-registration for walk-in patients at fixed sites or health facilities, H stands for House-to-house registration using volunteers as an additional push to rapidly increase the e-registration [16].

Health workers and front-line responders began receiving the vaccine days after it arrived in Lagos on the 12th of March, 2021 [13], as in many other countries, where the rollout prioritizes essential workers [17]. Whilst Phase 1 of the vaccine rollout plan was initially conceived to include only healthcare workers, other front-line workers, ports of entry (air, land, and seaports), Military, COVID-19 rapid response team (RRT), laboratory network, policemen, petrol pump workers and strategic leaders, it was reviewed to include teachers, members of the judiciary and adults over 70 years of age. Gradually any adult above the age of 18 years was eligible for vaccination [18].

Aim

This study provides a realistic risk assessment of vaccine deployment to inform future COVID-19 vaccination success by qualitatively assessing the plan, process and progress of the vaccine rollout in Lagos Nigeria.

Materials and methods

This study was conducted from May to July 2021.

Background of the study area

Lagos State is situated in the South-Western part of Nigeria, It is divided into three senatorial districts made up of five administrative divisions namely; Ikeja, Badagry, Ikorodu, Lagos and Epe. It has 20 Local Government Areas (LGA) (16 urban and 4 rural) and 37 Local Council Development Areas (LCDA). The population of Lagos State in 2021 was estimated at 14,862,111 [19]. There are 4 public tertiary healthcare facilities, 31 secondary healthcare facilities and 277 Primary Healthcare Centres (PHC) in Lagos State. Of the PHCs, 57 are equipped as priority facilities known as ‘flagship’ centres to provide 24 hours comprehensive care services. These flagship facilities have referral linkages to the higher levels of care. Vaccine rollout in Lagos State was organised at the primary level of care. However, the COVID-19 vaccination in Lagos State was conducted in 88 health facilities across the state, which included PHCs and General Hospitals [20].

Study sites

The study was conducted at selected health facilities designated as COVID-19 vaccination centres and the administrative offices where the key informants in the vaccine plan were located.

Study design

This was a descriptive cross-sectional qualitative study.

Study population

The study was conducted among clients (vaccine recipients) at the designated COVID-19 vaccination centres, the frontline workers and administrators in the COVID-19 vaccination process in Lagos State.

Sampling methodology

Site selection

This was conducted by multistage sampling from the list of 88 COVID-19 vaccination sites in Lagos [21]. The LGAs where the COVID-19 vaccine was available were first stratified into urban and rural LGAs. Next, 7 LGAs from the urban LGAs and 1 LGA from the rural LGAs were selected by ballot, a total of 8 LGAs. Also, by ballot one vaccination site from each of the 8 selected LGAs was included in the study. Eight (8) sites in all were selected for the study.

Selection of discussants, interviewees and key informants

The study participants were purposively selected based on their involvement in the vaccine rollout programme. The clients were recruited at the vaccination centres right after they had received either the first or second dose of the vaccine after the study was explained to them and they gave consent. The interviewees and key informants were formally approached, by prior request via a letter, to be interviewed.

Data collection tools and techniques

Data collection was entirely a qualitative inquiry, from the clients through focus group discussions (FGDs), and from the frontline workers and key informants through in-depth interviews (IDIs) and key informant interviews (KIIs) respectively. Data about the experiences of vaccine recipients during the vaccination process and their understanding of the vaccine rollout phases collected through FGDs were moderated using an open-ended, easy-to-understand, non-judgmental, FGD guide. An unstructured moderator’s guide was used to explore providers’ perspectives on the vaccine rollout plan, process and progress through the IDIs and KIIs. The FGD guide and the moderator’s guide were produced from the knowledge of already existing problems related to the COVID -19 vaccine roll-out and from previous studies [22,23].

An FGD was preferred over individual interviews for the vaccine recipients so as to gather information beyond clients’ knowledge, attitudes and practice related to the COVID-19 vaccine and also explore their shared attributes and differences, if any, which otherwise would be impossible to examine [24]. The specific frontline workers required for our study in each PHC do not number enough to make up an FGD.

Focus group discussion

Eight (8) FGDs, with 8 clients in each group, were carried out, one in each of the selected PHCs. Men and women were included in each FGD. The discussions were held soon after the clients received the vaccine, on the same day of vaccination, in adequately spaced rooms or open spaces that provide privacy, comfort, good ventilation, and lighting. The facilitator guided the discussion to ensure that the discussion was engaging with each person participating adequately. Before the discussion, each participant provided written informed consent and was assigned a unique identification number to protect their privacy. The proceedings of each focus group discussion were recorded using an audio recorder. A note-taker documented the non-verbal expressions, moods and other physical gestures. Each FGD lasted for 30–45 minutes.

In-depth interviews

Three (3) IDIs were conducted in each of the selected Local Government Areas among the 3 main front-line health workers in PHC. In all, 24 IDIs were conducted. Each IDI lasted for about 35–50 minutes.

Key informant interviews

Three (3) KIIs were conducted among the 3 key officers in the Lagos State Ministry of Health. Each KII lasted for about 25 minutes.

Training of research assistants

The investigators (KOJ and OY) and research assistants underwent training on conducting FGDs, KIIs and IDIs. The training emphasized correct data handling and maintaining respondents’ confidentiality,

Data analysis

The FGC, KII and IDI recordings were transcribed verbatim in entirety capturing the nuances of observations and participants’ descriptions. Data transcripts were developed immediately after data were collected. The transcripts were reviewed by a team of four of the authors (OJK, YO, HA, and AO). Thematic analysis was done based on the framework approach [25]. Two of the authors present at data collection and two that were not present ensured transferability, considering the cultural or professional context of the participants [26]. The authors read the transcripts several times. First, the verbatim transcripts were read and reread for overall understanding, and so that the authors familiarized themselves with the details of the transcripts. The transcripts were then examined and coded to search for patterns (content analysis) identifying relationships and similar phrases based on a theoretical framework. The theoretical framework summarized the key concepts and theories surrounding vaccines, the rollout process, vaccine uptake and the factors mitigating the success of the exercise describing any possible relationships between these concepts. The framework is based on a literature review [6,7,10,16]. Next, by the process of indexing [27], the authors extracted identified units and interpretations from the transcripts. Thematic analysis was achieved by categorizing the identified units and interpretations into sub-themes, relational themes, and eventually meta-themes. This was followed by a summarisation of the findings into simpler, easy-to-understand sentences and finally these were synthesized and interpreted to capture the data that was contextually comparable to the original transcripts, notes and recordings. The team had several meetings to address and agree any discrepancies in understanding or coding to arrive at a unified report. No coding software was applied for data analysis, nor was participant feedback sought on the final interpretation of their responses.

Ethical consideration

Ethical approval was obtained from the Health Research Ethics Committee (HREC) of the Lagos University Teaching Hospital. Permissions were also obtained from the Lagos State Ministry of Health, and the Medical Officers of Health in charge of the health facilities. The participants were duly informed of the purpose and objectives of the study and were assured of confidentiality. Written informed consent was obtained from each participant. Participation was voluntary and withdrawal from the study was without consequences. A unique identification number was assigned to each client before the FGD, therefore their participation was anonymous.

Results

In this study 8 FGDs, 24 KIIs and 3 IDIs were conducted. The FGD participants were all adults (age range 22–65 years), mostly female (75.0%), male-female ratio of 1:3. The list of all the participants is presented in Table 1.

Table 1. Study participants.

Participants Number
Clients (FGD participants) 64
Frontline workers (In-depth interview participants) 24
Key officers (Key informant interview participants) 3

Client perspectives on the COVID-19 vaccine rollout program in Lagos

The results of the FGD provide information on the experiences and challenges of the COVID-19 vaccine recipients regarding vaccination and their perspectives on strategies for improvement. These results are presented in 3 broad themes: i) Knowledge of COVID-19 vaccination, recipient eligibility, vaccine availability (the plan, process and progress) ii) myths/misconceptions, vaccine hesitancy iii) Benefits, adverse effects and concerns about the COVID-19 vaccine.

Knowledge of COVID-19 vaccination, recipient eligibility, vaccine availability (the plan, process and progress)

Many of the respondents demonstrated knowledge of the COVID-19 virus stating that the vaccine can protect individuals against COVID-19 infection and reduce the morbidity and mortality associated with the infection. The clients expressed varying opinions about the planned eligibility criteria for vaccination, some stating that everyone is eligible for the vaccine while some others opined that those who are eighteen years and above were considered eligible for the vaccine, for example in FGD 1 (Ikorodu), clients had differing beliefs on the age for eligibility, ranging from 15 years and above to twenty years and above. None of the participants were clear about the criteria for prioritizing recipients.

Regarding vaccine availability, some clients expressed their worry about the sustainability of vaccine supply. FGD6 P4(Female, 40 years) stated, “The problem with this vaccination is that we are not producing it in Nigeria here if eventually this vaccine we are taking already is no more available how are we going to complete the doses? FGD6 P4 further stated, “How are we going make sure to get our second dose, this is the only challenge I have noted about it, we are supposed to make our homemade vaccines, that’s all. FGD8 P5(Female, 35 years) worried that “It is not everybody that will receive the vaccine.

Myths/Misconceptions about COVID-19 vaccine

Some of the clients reported that myths and misconceptions surrounding the vaccine’s safety and usefulness were fueled by misinformation which was a threat to the acceptance of the vaccine during the vaccine rollout, with many people alluding to the different conspiracy theories about the COVID-19 vaccine, for example, FGD2 P5(Male, 58 years): “What the people are saying (is that) because the (global) population [of the people] is too much … they want to use (a) style to kill people, you understand, so since they cannot (find) the way to kill people they want to use, … injection[s] or this vaccine to kill people, they say there is nothing likeCOVID 19”, FGD5 P1(Female, 40 years): “Some will even say if you take it for the woman you won’t be able to conceive any more”. According to the clients, the claims propagated through social media about the harmful nature of the vaccine were the major reason for vaccine hesitancy. They explained that the health educators played a good role in correcting the misconceptions during the process of community mobilization that was conducted in each LGA. Some of the clients expressed concern about the general distrust in the motives of the government regarding the vaccine and the uncertainty about the future effect of the vaccine on recipients. According to the clients, some religious leaders forbade their followers from getting the COVID-19 vaccine.

In this part of the world we tend to believe more in our religious leaders and I’ve seen, I’ve watched about three pastors (name not mentioned) that are saying don’t get vaccinated don’t take the vaccine and I know two of them that have been vaccinated yet they couldn’t go back to tell the populace that they had been vaccinated and advise them to go for the vaccine.FGD6 P8(Female, 33 years).

Benefits, adverse effects and concerns about the vaccine

The clients agreed to the benefit of the COVID-19 vaccine as the primary approach to protecting oneself against the infection, also stating that the vaccine reduces the burden of the disease should a person get infected, in terms of morbidity and mortality. They provided a further benefit of vaccination stating that it would help to reduce the strain on the health workers if fewer people got ill because of the vaccine, and that herd immunity would be achieved faster, FGD4 P2(Female, 32 years): “this virus we are talking about is a killer and when (people) take the injection it will protect them and others in the community when the number of people that have taken the vaccine increases among them”. It was also opined that vaccination would help improve the economy because people could return to work once vaccinated. FGD6 P1(Male, 28 years) “for (the) economy to be promoted people have to be vaccinated so they must be free to go out. So many people are not able to do their buying and selling, so all of such (work) was retarded by COVID-19

The clients mostly reported that the vaccines were completely safe, hence their willingness to receive the vaccine, FGD5 P5(Male, 55 years) reported, “No disadvantage, good for everybody”. However, some concerns were expressed by some of the clients mostly about the need for personal protection with face masks and hand hygiene after taking the vaccine. FGD2 P7(Female, 43 years): “I see it as a disadvantage because some people are feeling relax[ed] that so far as they have taken the injection, “I’m already protected” and so free to move with people… confident that, haa! so far I take the injection I don’t think I (need a facemask). Even in some health facilities, I mean the medical practitioners in some areas, they too are relaxed because they have already taken the vaccine” A few of the clients thought that for the vaccine to reach every citizen it must be made compulsory, FGD4 P7: ..making It compulsory for people to get the vaccine and people that are not vaccinated should not be allowed to enter social places”.

Perspectives of frontline healthcare workers on the COVID-19 vaccine rollout program in Lagos

The IDI results provide information on frontline workers’ perspectives on the vaccine, the community response and the challenges of the vaccine rollout and suggested strategies to mitigate the challenges. These results are presented in 3 broad themes: i) The COVID-19 vaccine in the control of the pandemic ii) Barriers to the success of the vaccination programme iii) Frontline workers’ evaluation of the plan, process and progress

The COVID-19 vaccine in the control of the pandemic

The health workers, all working directly with the Lagos state COVID-19 vaccination programme, expressed satisfaction with the provision of the vaccine for the protection of all including the frontline workers such as themselves. However, IDI 1 expressed concerns saying, “I think the disadvantage [of being vaccinated] is that some people that are vaccinated believe they are fully covered 100%, they don’t want to use their face masks anymore, they don’t want to wash their hands regularly, they don’t want to use their hand sanitizer, they believe they can just go everywhere without face mask”, given that hand hygiene and face coverings are required even after vaccination for the control of the pandemic. On the other hand, IDI 4 expressed dissatisfaction with the vaccine saying, “The disadvantage that I can talk about for now is that it’s not a 100% assurance that when you are being vaccinated against the COVID-19 you cannot be infected again.

Barriers to the success of the vaccination programme

The healthcare providers discussed their concerns about a successful vaccination rollout, stating that the vaccine uptake may be especially vulnerable to myths and misconceptions surrounding the vaccine propagated through social media. IDI 21 said, “Rumour mongering is one of the most serious barriers to mass vaccination, an important aspect of this is that we are not educating the immediate community”, and further said, “some say it will make them impotent, others say it will make them not see very well, kill them, kill pregnant women or their babies in the womb”. The health workers blamed misinformation for the very frequently seen behaviour they perceived as vaccine hesitancy, stating that correct information needed to be provided to individuals as a matter of urgency if vaccine coverage is to be achieved.

Frontline workers’ evaluation of the plan, process and progress

The scoring of the vaccination programme, when the frontline workers were asked as a general question to gauge their view, was mostly above average. IDI 18 gave a good score saying, “[it was] A smooth process. Out of 5 I will put it [the score] between three and a half and four”, while IDI 19 gave an average rating but found the process favourable saying, “A bit average because I like the process”. Commending the government of Nigeria and the state, the frontline workers noted that the provision of the vaccines to all the designated centres and the security at the vaccination sites strengthened the process.

Security-wise, Government really did well, at every post we have policemen”. IDI 10

The first phase is like a plus for our Government”. IDI 14

I am thanking the government, they should keep it up”. IDI 16

In terms of logistics, some of the frontline workers expressed dissatisfaction with the planning.

I think we didn’t pay enough attention to the logistics that were going to be involved, when I say the logistics am talking about down from the issue of the cotton wool that will be used, the gloves that will be used because we were supplied these things [not supplied enough of these things]. The main thing that you practically have in abundance is the vaccine itself, with the cards and bar codes and of course needles and syringes. ID1 17

We started the first phase and the first dose had an extension that wasn’t planned for, in not planning for that extension it also cost a lot of issues in terms of logistics and even the implementers who were to carry out the work for the extra ten days were not planned for. IDI 17

Perspectives of administrative providers on the COVID-19 vaccine rollout program in Lagos

The KII results focus on the provider (healthcare administrators) perspectives surrounding the COVID-19 vaccine in Lagos. These are presented in 3 broad themes: i) The COVID-19 vaccination rollout plan and process ii) Partners, funding and logistics iii) Progress; uptake, barriers and challenges

The COVID-19 vaccination rollout plan and process

The plan. The key informants outlined the vaccination plan as earlier detailed but highlighted the strengths as follows;

Training: The providers explained that the COVID-19 vaccination rollout in Lagos State started with the setting up of a committee made up of stakeholders in the health sector, tasked with capacity building to support the vaccine rollout through training of health workers. This process was initiated by a ‘Train the trainers’ exercise followed by a step-down training at each LGA, KII2:We had a training apart from the national training of trainers that was conducted for three days we also had the state level training, (at the) state level the NTOT, that is the national training of trainers, (it) is actually meant for key program officers in the state that will act as … facilitators for state…! state-level training so we also had the state level training for another three days where the people at the LGAs level that is the key implementers were trained”.

Four-phased rollout: It was explained that the COVID-19 vaccination was designed to be in 4 phases according to the vaccine rollout plan.

The TEACH Strategy: The key informants all understood the TEACH strategy which was adopted in the planning of the vaccine rollout in Nigeria and Lagos State, recounting that all the elements of the strategy were rightly implemented concurrently by the providers, KII2: “all these things are expected to go pari passu with one another. It is not (that) you do one phase before the next one”.

Super-sites: The key informants defined a super-site as a COVID-19 vaccination center created in each LGA to address the challenge of clients who had relocated due to work, change of residence, or any other reason who were yet to receive the second dose of the vaccine. They opined that clients’ details were easily traced because of the DHIS2 client data platform that was provided, KII2: “I[t’]s the best because worldwide, wherever you get to, all they need to do is to just capture your (bar) code and they get the information concerning that person. Going forward I will like to suggest that anything that has to do with health I think this process is the best…”

The process. The providers expressed mixed levels of satisfaction with the COVID-19 vaccination process, dissatisfaction mostly stemming from the internet network and electrical power issues, KII 1 saying, “COVID-19 vaccination [process] does not have any problem”. According to the key informant, the process was strengthened overall by;

Daily review meetings: These feedback meetings were reported to be conducted at the LGA, state and national levels to review the vaccination process and address challenges.

Electronic registration on the DHIS2 Platform: The key informants reported that the server was a formidable electronic registration technology designed for use in the vaccination process, explaining that once the biodata of the clients was recorded, a unique identification number and a QR code were generated and recorded in the vaccination record card given to the vaccine recipient while a tear back counterfoil card was retained at the clinic for record purposes. They believed that the process was innovative though inefficient due to the problems with the internet network, resulting in delays and prolonged waiting times at the vaccination centres, KII 3: “And we see that, … the client(s) weren’t even sure if (when) the whole process during the e-registration was successful”. Manual registration of vaccine recipients was reported as the temporary measure taken to mitigate the internet network server problems.

Personnel/implementers: One key informant reported that the health workers facilitated the process KII3: “Well! It’s been orderly like if you go to,… the site at …, you will see where we have,… various officers that are involved”. It was reported that trained personnel formed the teams working in the COVID-19 vaccination rollout exercise. Each team consisted of a supervisor, a vaccinator, recorder, crowd mobilizer, town announcer and security personnel. However, the constituents of a team were said to have been reviewed to include two recorders and no town announcers, given that the role of an announcer was no longer required after a few weeks, while independent monitors gave daily reports at evening review meetings. it was further reported that the strength in the process was in the Local Government Area vaccine teams which consisted of the Local Immunization Officer (LIO), the Disease Surveillance and Notification Officer (DSNO), the Cold Chain Officer (CCO), the Apex Nurses and the Medical officer of Health who were in charge of supervising and monitoring the vaccination process. The partners such as the WHO representatives, National Agency for Food & Drug Administration and Control (NAFDAC) and the State Technical Facilitators were reported to have also been deployed to each Local Government Area to assist in training, monitoring and supervision of the COVID-19 vaccination process to ensure its success.

Channels of reporting adverse effects following immunization (AEFI): It was reported that to observe for AEFI after immunization clients were required to wait at the vaccination centre for 30 minutes observation and advised to call the number on the vaccination card or visit the clinic for treatment if they observed any side effects after leaving the vaccination centre. According to the key informants, data on AEFI were collected through the line-listing database developed to monitor side effects, while the Med safety app [2830] was used for remote line-listing.

Partners, funding and logistics

Partners. The key informants reported that some partners also collaborated with the NPHCDA and the State Government to ensure a successful vaccination exercise, stating that the role of the collaborators was to support the COVID-19 vaccination programme with logistics, funding and monitoring. Some of the partners listed were the WHO, UNICEF, NAFDAC, etc.

The partners WHO, UNICEF, CHEA and all the other partners, they are also involved in supporting the process. KII 2

Funding. The key informants discussed the need for more funding to support the programme in addition to the current funding from the NPHCDA and the Lagos State Government, KII 1: “We also have to mobilize funds that will be used for (supporting) the vaccination (with COVID-19 vaccine)”.

Logistics. The key informants reported that the tools, materials, and kits needed for the vaccination process were supplied to all the vaccination sites in Lagos State. KII 3: “The vaccination sites have all the necessary materials to be used for [the] vaccination”. These materials included face masks, hand sanitizers, gloves, cotton wool, vaccination cards, registration forms and registers, portable tablet computers and android phones used to facilitate the registration of clients. It was reported that the vaccines were stored and supplied to the sites fully applying the cold chain system, which they described as intact, KII 2: “[The] vaccine was brought to the state cold store and it was saved at the approved appropriate temperature”, and adequate provision was made for security at these sites. Vaccine Accountability Officers, who function to monitor and ensure the cold chain of vaccines was maintained by each vaccination team, were trained to monitor and ensure vaccine safety and were reported to have been at every site. It was reported that through community support from the Local Government, some vaccination sites provided tents and chairs for clients waiting to be vaccinated, an action they considered commendable.

Progress; uptake, barriers and challenges

Most of the key informants were positive about the vaccination progress and were optimistic about coverage provided that the planning, logistics, supplies and public enlightenment required were optimal. KII 2 suggested “improvement of the vaccination process”. KII 3 suggested adequate and timely payment of the salaries of the workers. The bottom-up approach was recommended for consideration in future vaccination planning. Recommendations were made for incorporating the COVID-19 vaccination programme into the routine immunization programme already established at each PHC to reduce the cost of logistics and ensure the much-needed wider coverage. Also recommended were, local COVID-19 vaccine manufacture because of the large population in Nigeria, more vaccination teams and sites, gaining the support of partners and non-governmental organizations (NGOs) and Public-Private Partnership through the participation of the private health facilities in the delivery of the COVID-19 vaccination, KII 1 “in some countries they have the public-private partnership (that can aid) the vaccination (process) and then (the) citizens pay (a) token to get their vaccines because the government cannot afford (to do I all). (It is) one thing for the government to receive the vaccine from the partners … but the cost of even the logistics of carrying out the vaccination is even more (than) the cost of the vaccine itself, and government cannot continue (to provide vaccines)”.

Uptake. Vaccine uptake was reported as extremely low in some centres. The poor turnout for vaccination was perceived by key informants to be linked to poor awareness. They noted that the widespread vaccine hesitancy was due to rumors and misinformation surrounding the vaccine. KII 2: “they read the jargon here (on social media), “haa! I don’t want to take o, haa!” So that is why you find out that even at the beginning of the vaccination majority of people were skeptical. People were thinking, “let us look out (for) how many people will die after taking the vaccine”, so after waiting for about one or two months they see that nobody is dying, rather people are living in good health so the majority are now registering (to take the vaccine)“. The key informants recommended that public enlightenment through vaccination campaigns to aid the progress of the vaccine rollout was the surest approach to improving vaccine uptake using social media and the time-tested traditional broadcast media through rallies, market campaigns, billboards, fliers, talk shows, etc. were recommended. The information being broadcast should aim to debunk the wrong information being propagated. The concept of Vaccine Champions was introduced by KII 1 as “well-known, role models and reputable people who have received the vaccine and who will promote the vaccine uptake by encouraging people to get vaccinated”.

Barriers. Aside from challenges related to planning, a few barriers notably poor public awareness, misinformation, myths and misconceptions, logistics, poor internet connectivity, poor electricity supply, lack of functional tablet computers, and in some cases, inadequate consumable materials like cotton wool, gloves, vaccination cards, QR code generation, face masks and the vaccines at some sites, and finally, poor staffing were reported.

In addition to misinformation, AEFI such as pain at the injection site, headache, weakness, excessive eating and excessive sleeping were reported as major factors leading to vaccine hesitancy and poor uptake even though only a few serious complications like fainting and other situations requiring hospitalization were reported.

Challenges. The challenges associated with the COVID 19 vaccination were termed social, psychological and economic.

Social challenge: A key informant reported the stigma associated with receiving the vaccine caused clients to receive the vaccine in secret because they feared rejection from their families. KII 3: “Rumor is being spread that for those who received (the vaccine) will die and all that, it will also affect their social life”, “(a client said) they received (a phone) call from a cousin saying that they are going to die because they have been vaccinated”. Stigmatization was viewed as disruptive to the vaccination rollout process.

Psychological challenge: A patient-related challenge to the entire COVID-19 response highlighted by key informants was that despite contrary information, people who were vaccinated let their guards down in terms of observing COVID-19 protocols such as hand washing, social distancing, wearing of face masks, etc. Also, some individuals delayed receiving the second dose of the vaccine because they were psychologically unprepared for it, KII 2: “some usually have [a] fever and then pain at the site of injection and then we also have reports of people throwing up, eating more than expected, sleeping and then headache and so on and so some are afraid of the second dose”, owing to the side effects they experienced with the first dose.

Economic challenge: A key informant expressed concern over the seeming imminent requirement of vaccination for travel and tourism and the sustainability of the COVID-19 vaccination exercise because of the high cost associated with the vaccination rollout process, KII 1: “I’ve told you about how it [the COVID-19 vaccine roll-out process] affects us socially and economically and that is why the government cannot continue to support and to spend money on it because it’s affecting other spheres of life, (it) is affecting the other sectors, for example, we have huge unemployment (due to COVID-19). People who were employed before (have) lost their jobs, and (it) is very difficult for people to even earn a living so (the) government (has to) put money in other sectors so that the economy can come up”, also stating that proper planning informed by adequate monitoring and evaluation is needed to ensure the success of mass vaccination.

The perspectives of the clients and providers of COVID-19 vaccination about the vaccine rollout plan, process and progress, as well as the suggested strategies to address the identified challenges, gathered through the FGDs, IDIs and KIIs are as summarised in Table 2.

Table 2. Summary of client and provider perspectives on the challenges of the COVID-19 vaccine rollout plan, process and progress and strategies to address the barriers to successful vaccine rollout.
Thematic area of reported Challenges Challenges of the COVID-19 vaccine rollout Strategies to address the barriers to successful vaccine rollout
Client perspectives
Recipient eligibility
Confusion about the categories of individuals eligible to receive the vaccine. Community-level enlightenment campaigns and community mobilization.
Vaccine availability Too few doses were available for the huge population of people in Nigeria. Local vaccine manufacturing.
Myths/misconceptions Misleading information about the vaccine propagated especially on social media leading to vaccine hesitancy, and apprehension about the second dose. The deliberate provision of adequate and correct information about the vaccine.
Making the vaccine compulsory.
Conspiracy theories Distrust in the health system and the government causes people to ignore vaccination. Community enlightenment campaigns, transparency in governance, leadership with integrity
Provider perspectives
    • Frontline workers
The degree of protection offered by the vaccine
Vaccination creates a false sense of security from the infection so people no longer want to apply safety measures. Continuous health education
Vaccine uptake Poor vaccine uptake due to myths and misconceptions among members of the community Urgent correct public enlightenment
Frontline workers’ evaluation of the plan, process and progress Participation is limited by poor logistics.
Insufficient and inconsistent supply of consumables.
Unplanned changes and the extension of the first phase disrupted the original plan.
Better planning, backed by correct and accurate data.
    • Administrators
Completing vaccination doses Clients are at risk of being lost to follow-up for the second dose of the vaccine. Strengthening and creating more supersites.
Use of electronic data capturing Poor internet data network and electrical power supply resulting in delays and prolonged waiting times at the vaccination centres. Developing an alternative and appropriate technology that does not depend on the inconsistent power supply in the country.
Improvement in internet network in the country as a whole.
Partners, funding and logistics The limitation in the logistics related to inadequate funding More collaborations and funding to support the program
Evaluation of the progress; uptake, barriers and challenges Inadequate supply of consumable materials like syringes, a reflection of the need for collaboration. The bottom-up approach is to be applied in planning so that the steps taken are more locally appropriate.
Future COVID-19 vaccine integration into the routine immunization programme to reduce the cost and ensure coverage.
Vaccine uptake and coverage Vaccine hesitancy due to poor vaccination information.
The stigmatization of vaccine recipients
Psychological challenges associated with receiving the vaccine.
Poor internet connectivity, poor electricity supply, lack of functional tablet computers, inadequate consumable materials like cotton wool, gloves, vaccination cards, QR code generation, face masks and poor and insufficient staffing.
Targeted vaccination campaigns with social media and broadcast media sensitization to debunk myths.
‘Vaccine champions’ to
address stigma.
Counseling before and after vaccination.
Rigorous monitoring and evaluation of the vaccination process for future planning

Discussion

This study sought to examine the challenges of COVID-19 vaccination rollout in Lagos, Nigeria from the point of view of clients and healthcare providers. The complexities of the factors that have affected the vaccine rollout are demonstrated in the findings, bringing to light the challenges observed by the vaccine recipients, the frontline health workers and the health administrators in Lagos State. The challenges were related to vaccine recipient eligibility, vaccine availability, myths/misconceptions, conspiracy theories, concerns about the degree of protection offered by the vaccine, vaccine hesitancy, uptake and coverage, completing vaccine doses, the use of electronic data capturing, the role of international partners, funding and logistics. The primary findings of this study align with the challenges, barriers and facilitators reported in the 49 African countries that started rolling out COVID-19 vaccines in early 2021 [6]. Several previous studies in various parts of the world and Africa have identified challenges both systemic and individualized including vaccine hesitancy and inadequate fact-based information on the benefits and risks of the COVID-19 vaccine. Some studies have suggested that vaccine hesitancy may be particularly prevalent in low-income countries like Nigeria [31], where our study was conducted, precipitated by factors such as distrust in vaccines [32]. Unfortunately for countries in Africa from December 2020, even before doses of the COVID-19 vaccines became available in Africa, the global movement against the vaccine had created a breeding ground for vaccine hesitancy as was the case in Nigeria [33]. This growing concern remains a threat to the vaccine rollout even after several months into the process. One study found that fear is significantly correlated with the lack of accurate vaccination knowledge leading to a poor perception of the importance of vaccination and a lower likelihood of vaccine uptake [34].

Studies also reported challenges related to the operational plan for vaccine rollout [35,36], along with vaccine shortages, poor logistics and supplies [37]. However, poor internet network was the most limiting challenge reported in our study causing poor linkages between internet servers and external facilities, hence a resort to paper registration. The electronic registration for COVID-19 vaccination is a novel technology in the immunization history of Nigeria, therefore the challenges experienced during the first phase of the vaccination process are such that can be addressed and improved upon in subsequent vaccination exercises.

Having adequate knowledge about vaccination has the potential to increase vaccination uptake directly by addressing misconceptions and providing clarity on the vaccination schedule or indirectly by helping eliminate the fear of vaccines. One of the most common vaccine-related misconceptions is that the benefits of vaccination are minimal compared to the often-exaggerated risks and that vaccination is inferior to natural immunity acquired from surviving a disease [38]. This study however reports concerns about misconceptions from misleading information about the side effects of the vaccine, propagated especially on social media, leading to vaccine hesitancy and apprehension about taking the second dose of the vaccine. These misconceptions have led to a distrust in the government and the health system causing people to ignore vaccination, though the turnout for vaccination was very impressive at some vaccination sites. However due to misinformation and misconceptions similar to that found in other countries that are involved in vaccine rollout [39,40], the vaccination process was somewhat limited such that in some centres turnouts were particularly poor. Among the factors that affect vaccine decision-making, cultural, social and vaccine-specific factors play a minimal role when people do not trust the vaccines available [41]. The term vaccine confidence refers to the trust that clients and providers have in vaccines, the vaccination process, the health workers who administer the vaccines, vaccine production and policies [42]. It stems from an understanding of the importance of building trust in COVID-19 vaccines. Vaccine uptake is improved with increased vaccine confidence [43] leading to reduced COVID -19 morbidity and mortality. To promote vaccine confidence the risk communication about the vaccine should be clear [44] as recommended by participants, such as in their local language or using tailored language that they can easily understand [45]. The local language can be used to address the myths, misconceptions, rumors, misinformation and disinformation surrounding the COVID-19 vaccine.

Other studies investigating predictors of vaccination uptake, and factors associated with poor vaccination coverage found that the perceived severity in terms of the high morbidity and mortality of a disease such as COVID-19 may reduce vaccine hesitancy [46], demonstrating that vaccine uptake is highest before and during a pandemic, and immediately after a new vaccine is available to control the pandemic [47]. This knowledge should inform the action of the healthcare community to capitalize on this predictable early COVID-19 vaccine enthusiasm from the public to proceed with vaccine rollout using a well-organized, rapid vaccine distribution plan [48]. In Lagos State, full vaccination was facilitated by mitigating dropouts, using ‘supersites’ created in each of the Local Government Areas of the state to address the issue of second dose vaccination.

Aside from health system-centered challenges, clients reported barriers to vaccine uptake, notably, AEFIs. The vaccine’s side effects were mostly minor, for example, the more frequently reported symptoms like fever, pain at the injection site, headaches, excessive sleeping, excessive eating and weakness, none lasting beyond forty-eight hours. While more serious side effects were less frequently reported, a few cases of severe AEFIs requiring hospital care were documented in some centers including fainting, collapsing and difficulty in breathing.

Another challenge discussed among study participants is that the COVID-19 vaccine doses may remain perpetually insufficient given Nigeria’s dense population. However, vaccine rollout can progress to reach all citizens with good planning, adequate funding, an efficient vaccine cold chain system and logistics that take into cognizance the differences at the local, state and national levels.

The administrators recommended that the citizens are carried along and their opinions included in the vaccination planning process describing a bottom-to-top approach. This is effective as shown in a vaccine study that shows that the bottom-up strategy outperforms the top-down strategy in community vaccine acceptance and involvement in vaccine programmes [49]. This study revealed that the vaccination process can also be improved upon with the provision of more healthcare teams, more vaccination sites and better logistics.

One approach that may be important is that COVID-19 vaccination should be incorporated into the routine immunization programmes that already exist in Nigeria. This would promote wider coverage and decrease the cost of vaccination and therefore, the funding needed by resource-constrained countries like ours. Furthermore, integrating COVID-19 vaccination with routine immunization would potentially prevent collateral disruptions in other essential services like childhood immunization, antenatal care, etc., which are offered at the primary health care facilities, the sites for vaccination in the State.

Although the majority of the participants in this study were not in support of making vaccination mandatory a few participants suggested enforcing it. This opinion has been expressed by several writers, some specifying their recommendations to several priority groups like health workers and care home workers [50]. Participants suggested that public-private partnerships can be used to ensure a sustainable vaccination process because the government may not be able to bear the cost of vaccine delivery in the long run. This opinion may have been influenced by the numerous examples of the successful interface of the government and private organizations in healthcare provision in many settings in Nigeria [51,52] and globally [53,54]. COVID vaccine rollout would be similar to these examples in the sense that the limitations of poor funding would be eliminated through these partnerships. Nigeria and indeed other countries can learn from our findings to leverage available resources, and ensure that development is ongoing and can compete with other nations in the world, placing priority on measures such as education and literacy.

Conclusions

The vaccination process though without major threats was limited by internet network problems which affected the electronic registration. Misinformation and misconceptions were recognized as some of the barriers which created vaccine hesitancy. The AEFIs reported were mild. The participants recommended continuous public enlightenment to provide fact-based vaccination information to help build trust and confidence in the COVID-19 vaccine. Valuable lessons are emerging from the rollout process including the importance of the bottom-up approach in planning, more teams, more vaccination sites and more vacccines to ensure a wider reach and coverage.

Acknowledgments

All respondents for their participation in the study.

Data Availability

All the data gathered for this research is available on request but cannot be made publicly available for ethical reasons, to protect the participants’ privacy. The public deposition would breach compliance with the protocol approved by our research ethics board and would compromise participants’ privacy as they would easily be identified. The name of the ethics committee or Institutional Review Board that provided ethical approval for our study is Health Research Ethics Committee, Lagos University Teaching Hospital, Idiaraba, Lagos, Nigeria. A non-author point of contact that is able to receive queries regarding data access is Prof. Oyinkansola Sofola (+234 8033031483, osofola@unilag.edu.ng.

Funding Statement

Funding for this study was provided by the Lagos State Government. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0000486.r001

Decision Letter 0

Muhammed O Afolabi

23 Feb 2022

PGPH-D-21-01166

A qualitative analysis of the COVID-19 vaccination rollout in Lagos, Nigeria: Client and provider perspectives on the plan, the process and the progress

PLOS Global Public Health

Dear Dr. Oluchi Joan Kanma-Okafor,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 23 March 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammed Olanrewaju Afolabi, MD, MPH, PhD

Academic Editor

PLOS Global Public Health

JOURNAL REQUIREMENTS:

1. Please update the completed 'Competing Interests' statement, including any COIs declared by your co-authors. If you have no competing interests to declare, please state "The authors have declared that no competing interests exist".

2. In the online submission form, you indicated that "Data is available on request but cannot be made publicly available for ethical reasons, to protect the respondents.". All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons by return email and your exemption request will be escalated to the editor for approval. Your exemption request will be handled independently and will not hold up the peer review process, but will need to be resolved should your manuscript be accepted for publication. One of the Editorial team will then be in touch if there are any issues.

3. Please amend your detailed Financial Disclosure statement. This is published with the article, therefore should be completed in full sentences and contain the exact wording you wish to be published.

i) Please include all sources of funding (financial or material support) for your study. List the grants (with grant number) or organizations (with url) that supported your study, including funding received from your institution. 

ii). State the initials, alongside each funding source, of each author to receive each grant.

iii). State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

4. Please ensure that the funders and grant numbers match between the Financial Disclosure field and the Funding Information tab in your submission form. Note that the funders must be provided in the same order in both places as well.

REVIEWERS COMMENTS:

Reviewer #1:

Overall, this paper focuses on the COVID-19 vaccination rollout in Lagos from the perspectives of vaccine recipients, HCWs, and government officers. Overall, the authors did a great job providing and presenting a lot of data on the rollout; I particularly like the inclusion of different perspectives. Some of the language can be cleaned up throughout, but overall, I think it’s a paper the authors should be proud of and is one that will benefit future vaccine rollouts in Nigeria and elsewhere.

Some detailed comments are provided:

Introduction

- Line 80: Provide a little more detail – perhaps the number of vaccines currently produced (can say “at the time of writing”) to provide context of scale

- Lines 80-84: Can you be more specific? Is this clinical data? Consider breaking the sentence into two separate ones for clarity.

- Line 84: were the blood clots discredited, or was it reports that it was unsafe? Please clarify.

- Line 85: Is it possible to be more specific than “Africa”? Maybe “Vaccination against COVID-19 has been slower in countries relying on doses from COVAX than in other places” or something like that.

- Lines 88-89: This is a very important point, but the sentence is unclear. What proportions are you speaking of?

- Line 90: An example of an exemplary rollout would be helpful.

- Lines 91-95: This sentence needs some citation(s), as there have been several reports about why the rollouts/administration may have been delayed – including, but not listed here, countries receiving vaccines right before they were to expire.

- Line 96: Which vaccine was provided?

- Line 106: Did Lagos State receive their share immediately?

- Line 124: When did the vaccine become available to all adults?

- COME BACK TO AIM/LINE 125

Methods

- Overall, the divisions and sub-divisions are a bit unclear. Consider combining some sections or making note of how sub-sections may fit into broader sections (using numbers and/or letters).

- Line 134: Lagos city or Lagos state?

- TOO MUCH INFO? Perhaps link to rollout more and cut the rest… And then connect with study sites

- Lines 158-162: What does it mean to be formally approached? How was that different than approaching vaccine recipients?

- Data collection tools and techniques: I’m a little confused by “qualitative inquiry.” You mean the qualitative data were collected using a guide, correct? Was this guide structured or semi-structured? Please provide a little more detail on the key topics addressed in the guides and how they differed between IDIs and KIIs. Same can be said for the FGDs – please provide a little information on key topics covered.

o Where FGDs held the same day as the recruitment of participants? Or did participants return on a separate day?

- Line 180: The number of IDIs, etc. carried out should be included in the results section. Also, if there were 8 sites and 4 IDIs were carried out at each site, why were 24 conducted (rather than 32)? 24 is still a lot of IDIs, but please comment if there were decliners or a reason why the numbers do not match.

- Lines 183-186: Is there a way to not include their titles? I imagine this makes the KII participants easy to identify… Please be more general in how they are referred to.

- Lines 191-192: Please clarify. “Transcribed verbatim” means word-for-word, so by the rest of the sentence, do you mean that the other notes (e.g. non-verbal cues, etc.) were included into the transcripts as well?

- Line 196: “manuscripts” should be changed to “transcripts”

- Lines 199-207: There is a lot of detail here that I believe can be written/edited in a way that is more succinct and clearer to the reader.

o If no coding software was used, did the authors use Word or Excel?

Results

- The number of KIIs, IDIs, FGDs should be included at the beginning of the results section. Here you can also include some summarized information on the participants (gender, age, etc.)

o Were men and women included in the same FGDs?

o What is the gender breakdown of the IDIs and KIIs?

o I’m still worried that by providing their titles, the identity of the KIIs is easy to figure out.

- Lines 252-254: did the participants themselves have concerns about the government’s motives or the uncertainty of the effect, or was it what they had heard from others? If they had these concerns, what led them to still get vaccinated?

- In this section (myths/misconceptions), it would be helpful to have a specific example or two. Participants seem to have heard of the myths (did they mention any specific myths?) but still got vaccinated. Did anyone say why that was?

o OK, this is mentioned in the next section. Was it the same respondents?

- Lines 303-305: Was this hesitancy the HCWs had seen while working in the clinic – was it directly observed by them? Or was this more of an explanation for wider vaccine hesitancy?

- Lines 308-311: Were participants asked to score the programme during the IDIs? Was this a formal assessment, or was it part of the interview questions? If it was formal, please say more on that and include it in the methods section.

- Line 323: should there be “not” in that sentence?

- Lines 339-351: Since the steps are already mentioned in the intro, I think this section can be cut. Or, the focus should not be on repeating the steps, but on the KII participants’ views on how this went, barriers/successes, etc.

- Section from KIIs in general, lines 331-461: I have a few concerns about this section.

o First, there is a lot of space given to what was only 3 KIIs in comparison to the IDIs and FGDs. Much of the first part is just a summary of the process that occurred, much of which is included in the intro. I think what is most relevant for the study can stay in the intro and then the rest can be removed and instead placed in a figure or text box, possibly to be included in the annex or as supplementary information.

o The parts that bring up the KII participants’ opinions on what went well and what can be improved upon are good and could be elaborated on – especially as their comments relate and compare to what the IDI participants said.

o Lines 423-425: is this the opinion of the participants? As it reads, it sounds almost like they are summarizing a study they did.

o I’m not sure what is different between “barriers” and “challenges.”

- In general, the sub-sections of the Results all follow the same order of plan, process, and progress for each group of participants separately. Something to consider would be blending the results from the different participants so they can be compared and contrasted as it relates to this overall main outline (plan, process, progress). This would keep make the results more succinct, allow for comparison between different groups of respondents, and make the sections and sub-sections easier to follow.

Discussion

- Overall, there is a lot of information in the discussion, but I feel it’s typically very broad and general. I think this section would benefit a lot from clear examples in the literature and how those examples link directly with the data presented in the results.

- Lines 480-481: Sentence needs to be written more clearly.

- Lines 502-507: Are there other reasons why certain sites had better turnout than others? Was it only do to misinformation, or are there structural factors that may play a role?

- Lines 507-508: Citation?

- Lines 513-516: Can you be more specific? Perhaps include more of the information participants gave regarding how or what they want included in vaccine messages and how the rollout may address those issues in the future.

- Lines 517-520: I’m not sure I understand this sentence… How does high morbidity/mortality lead to a reduction in vaccine hesitancy? Also, this is a rather old source – is there anything newer that addresses this issue, particularly as it may relate to COVID?

- Lines 526-531: Is it the AEFIs themselves, or people’s perceptions of the AEFIs that is most important for vaccine uptake?

- Lines 536-541: I find that participants wanted a more bottom-up approach interesting. Was this something that the KII participants discussed too? Is there a way to compare/contrast this desire with the plans of the rollout?

- Lines 542-548: Have there been any studies about incorporating other vaccines into routine immunization?

- Lines 552-556: Can you provide an example of the use of these types of partnerships? How would COVID vaccine rollout be similar or different from these examples? Are there importance lessons that can be applied?

- Overall, how can other countries learn from Nigeria? This study gives details on many challenges and lessons learnt – how can other countries benefit from this information? How can Nigeria benefit from this information in the future?

Reviewer #2:

This paper reports on a qualitative study that assessed the plan, process, and progress of the COVID-19 vaccination program in Lagos State Nigeria. Using in-depth interviews and focus group discussions, the authors highlight, from the perspectives of vaccine recipients and healthcare workers, the challenges to the COVID-19 vaccine implementation program in Lagos State including issues around vaccine hesitancy and logistics. Factors that contributed to the success of the program are also presented. The study is novel and has interesting and important findings that could be used to inform future vaccine programs in Lagos and Nigeria generally

The presentation of the paper however needs to be improved in terms of structure, additional information in the Method’s section, and support (quotes from IDIs and FGDs) for some of the key results. My comments are as follows:

• Going through the results and certain sections of the abstract, it became less and less clear if the manuscript is reporting on the outcome of research or a monitoring and evaluation exercise. Perhaps this is because of the way the results are presented (especially the choice of words). For example, participants agreed, commending the government of Nigeria, and detailed descriptions of the actual roll out program instead of presenting the perspectives of the different stakeholder groups without the authors qualifying them as: “genuine” “successful, “unfounded claims” etc. Also, where the authors present the results of IDIs with healthcare workers and key informants, there is an inclination to provide a defence to most of the challenges mentioned by the interviewees. That may be okay, if those reasons are provided in the discussion section for example… although in the interviews, participants mentioned that XXX was a major logistic-related challenge, from our knowledge and experience of the roll out program, this challenge may have been due to XX and was resolved by XX.

• Following up from the point above, it is important for the authors to describe their positionality in the context of this research. For example, were some of them involved in the vaccine roll out program and if so in what capacity and how this may have influenced the results or discussions? This will give researchers some perspectives on the overall narrative and arguments advanced in the paper.

• The methods section needs more information:

• Line 159: vaccine rollout process or vaccine roll out program?

• Line 160: It seems to me like two sampling strategies were used. Purposive (frontline workers) and convenience (clients/vaccine recipients).

•Line 161: Participants were formally approached- What does this mean? -A description of the process and why that was necessary will provide more clarity

• Line 164: Delete “For the qualitative inquiry”. The title already states that it is a qualitative study. Also, only qualitative methods were used

• Line 164: Moderator’s guide: What was the nature of this guide? Semi structured, open ended or close ended? What type of questions were included and how was it developed?

• Line 165: State the number of IDIs and KII. What was the difference between the two? was it in the method or in the stakeholder group interviewed? If in methods, then I suggest that should be described. If it is in the stakeholder group, then I suggest you use IDIs across the paper.

• The methods section should have a justification of why different methods were used for the different stakeholder groups. For example, why FGDs with vaccine recipients and not IDIs. Similarly, why IDIs with frontline workers and not FGDs. Also, it needs to be stated clearly at the introduction that FGD were conducted with vaccine recipients only and IDIs with healthcare workers and key informants (Administrators?) only. Otherwise, it becomes confusing who was involved in what, especially in the results section.

• How long were the IDIs and KIIs? This information was provided for FGDs but not the other methods.

• How did the authors arrive at the final sample size for each stakeholder group and in the case of FGDs, why 8 participants per FGDs?

• What was the overall study period? When were the FGDs conducted, was it immediately after vaccination? If yes, how were participants selected from the overall pool of persons who presented at the vaccine site on that specific day?

• What was the criteria for selecting the key officers? That is how did the team decide who was a “key informant”? for example why the state epidemiologist and not the Commissioner of Health or the Head of the Nigeria CDC?

• Line 188: Were all the Investigator part of the training or only those responsible for the conducting the FGDs, KIIs etc If not all, consider indicating the initials of those who were trained for this purpose.

• Line 195-196: What does transferability for cultural reasons mean and what impact did this have on the thematic coding and data analysis.

• Line 196: Read the manuscript (transcript?)

• Line 199: A description of the theoretical framework is important to give readers a perspective of the analysis. Is it an existing framework that has been published or used in similar studies or was it developed during the coding process by those involved in the analysis? - If so, was it developed etc. It will also be important to state if the thematic coding was inductive or deductive.

• Line 200: The sentence, “Next, by the process of indexing. This process of indexing needs to be described or referenced for the benefit of your readers.

• Line 203: What is understandable data? Either provide a description or provide a reference of what it means in the context of qualitative research.

• Line 205: Were the several meetings with the four team members involved in the coding or all the authors.

• Line 213: Purely voluntary- I suggest purely be deleted except it goes beyond voluntary.

Results:

• Table 1: Headings in Column 1 are not consistent- In one instance the method is used, in another the name of the stakeholder group. I suggest the authors use 1 across all groups, preferably the stakeholder group (Vaccine Recipients; Front line health care workers etc)

• Overall, the presentation of the results is confusing. It is presented according to the Methods. I suggest the headings should rather be defined by the different Stakeholder Groups. For example, “Perspectives of vaccine recipients on the COVID-19 vaccine rollout Program in Lagos”; “Perspectives of frontline healthcare workers on the COVID-19 vaccine rollout Program in Lagos” etc.

• Line 234: Introduce a quote from the FGDs to support the statement.

• Line 245: The theme needs to be rephrased to capture the goal of the project (COVID-19 vaccine roll in Lagos). For example, “Myths or misconceptions about COVID_19 Vaccine and the impact on the vaccine-roll out program in Lagos State”. The paper is on the vaccine roll out process and not COVId-19 vaccine hesitancy. How it leads to hesitancy can then be captured in the narrative rather than the sub-heading (a key theme)

• Line 249: A supporting quote should be inserted at the end of the sentence “…… conspiracy theories about theCOVID-19 vaccine” to support the analysis/narrative

• Line 249: Sentence starting with 'Unfounded claims'…. I suggest that as much as possible, the authors should remain value neutral in presenting the results and avoid the use of words like “unfounded” except that was used by the participants and there is a supporting quote for that. That phrasing, if necessary, can be used in the discussion section with a supporting argument on why they are considered “unfounded”. I think here is an opportunity by the authors to educate, rather than then dismiss a claim as unfounded” because such dismissals could entrench covid-19 vaccine hesitancy or resistance.

• Line 250: Participants mentioned that..….. Was this all or some, or most of the participants? This applies across the manuscript.

• Line 267. Sentence ending with “achieved faster” needs a supporting quote. Throughout the results, please provide supporting quotes for each result.

• Line The statement “It was also opined that vaccination would help improves the economy…” also requires a supporting quote

• As mentioned earlier, consider replacing In-depth Interviews with a description around the lines “Frontline Workers' Perspectives on COVID-19 Vaccines the roll out program in Lagos Nigeria”

• Why are supporting quotes from the IDIs not reported in the same way as the FGDs? The FGDs for example had the gender and age of the participants in addition to the unique participant number, while the IDIs only have the unique IDs. This needs to be consistent across the paper. Analysis in terms of age and gender are also not presented, so it is hard to tell why the authors reported the FGDs using gender and age.

• Lines 314-318: Up to three quotes are provided to support the results that HCWs commended the government, and all quotes are very similar. I suggest one quote is used for this purpose especially as in most cases, just one quote is provided for a key result- and in other cases no quotes.

• Lines 320- Kindly provide description on the specific aspect(s) of planning that came up from the interviews before providing a quote. One quote should be okay.

• Line 331: Instead of key informant interviews, consider using “Providers Perspectives on COVID-19 Vaccine Roll out in Lagos Nigeria”

• Line 332: Considering the length of this manuscript and readers may have forgotten which stakeholder groups were described as “Providers”, It is important, for the purpose of clarity, to repeat that information in this sentence - May be important to repeat it here for clarity.

• Line 339-351: I suggest the paragraph be deleted as it doesn’t form part of the key results nor adds value to the results. Same for like 357-359.

• Line 367: Please provide a supporting quote.

• Line 370-71: Why was there a need to review the process? I think that is the key information as the article reports on vaccine roll out process.

• Line 386: Issues around logistics has already been reported. Also, Lines 397-407 seems to be an evaluation of the logistics rather than the perspectives of the key informants. I therefore suggest that the paragraph be deleted.

• Lines 442: Please provide supporting quote

• Lines 443: For the entire section, please provide supporting quotes for each of the key results.

• Lines 450-453: It is not clear how failure to observe COVID-19 protocols by the already vaccinated, was a challenge to the vaccine roll out program in Lagos. That will need further explanation.

• Lines 469: The word client has only been introduced in the discussion. My guess is that this refers to vaccine recipients. However, I think, the authors should opt for one description for that stakeholder group and use it throughout the manuscript.

• Overall, the use of “participants” across the results section is confusing, I suggest it should be replaced with the title of each stakeholder group that is being referred to.

• Generally, it is not clear why the results were analysed and presented separately for each stakeholder group? Why was that important and what extra value does it bring to the narrative on COVID-19 vaccine roll out in Lagos. This needs to come out clearly in the introduction and discussion especially as some on the themes are similar across stakeholder groups. If there are no specific reasons, the authors should consider reporting the results by thematic area only and supporting quotes should indicate if it was a HCW, key informant or vaccine recipient.

Reviewer #3:

This is a very interesting and important article, outlining in great detail the complexities and successes of delivering COVID-19 vaccination in Lagos. I think the article could state its contribution even more strongly, by noting its originality in bringing together perspectives of vaccine recipients and those involved at different levels of the vaccine delivery system. Emphasising the contribution will also require the authors engaging a bit more thoroughly with the social science literature on vaccine confidence and delivery - the Vaccine Confidence Project (https://www.vaccineconfidence.org/) can be a good start, and literature by Heidi Larson and colleagues includes some good overviews of the literature.

The area where I think some major revisions are required is in the interpretation of the data. This will not require a great deal of re-analysis, but rather really considering what the data is saying and what it is not. It seemed to me that having interviewed vaccine recipients and providers, the authors cannot in fact suggest to have insight into drivers of vaccine hesitancy. Discussions of conspiracies and mistrust are *reported* by respondents but not in fact stated as reasons for *their* refusal. They are in other words speculations about low uptake. For example on page 20 you state “the poor turnout for vaccination was because awareness was low”— but you haven’t actually explored reasons for refusal/hesitancy with those who refused, so you can only really say that poor turnout was perceived by key informants to be linked to low awareness.

Research has shown that healthcare providers might overstate low awareness when reasons for hesitancy are more complex (see for example Enria et al "Bringing the social into vaccination research" in PLOS One). It does not mean that the fact that providers and vaccine recipients deem this to be significant is not worth stating, but it needs to be interpreted as their speculation rather than as a finding that this is what you take to be the most important issue affecting vaccination uptake. The respondents' description of their encounters of misconceptions in practice are valuable, but need to be interpreted as such, given that they did not in fact drive their own vaccination behaviour (everyone you interviewed is pro vaccination). Is there any data available on uptake in the facilities you studied and the relative significance of supply and demand issues? On page 27 you note “poor uptake”—can this be quantified? Were any access issues reported in your findings? Is there any research you could cite that offers more concrete evidence on the hesitancy problem, if this is indeed a large problem in practice? I thought that it was extremely interesting that your respondents worried there might not be enough vaccines for everyone—how does this relate to concerns about mistrust?

Related to the question of potential hesitancy, I would suggest that you consider a more nuanced interpretation of mistrust in vaccination. There may be more complex reasons why people have low trust in vaccination, and indeed there is very good literature on this from Nigeria as well, which situates for example the polio controversy (see Obadare E. A crisis of trust: history, politics, religion and the polio controversy in Northern Nigeria. Patterns Prejudice. 2005;39(3):265–84.) or broader literature that contestes the “knowledge deficit” model (see Goldenberg M. Public Misunderstanding of Science?: Reframing the Problem of Vaccine Hesitancy. Perspect Sci. 2016;24(5):552–81.). You can consider this in the discussion, but as noted above, I would also treat the issue of mistrust much more carefully, with a more nuanced interpretation and perhaps not make it your central finding as I am not sure that is what your data suggests.

Some smaller isses that you could fix:

- Because you are reporting data from very different kinds of respondents, I would make sure that throughout you make clear which you are speaking of—so for example on page 20 instead of saying “most of the respondents”, clarify that this is among key informants

- P.5 why is this study framed as a “risk assessment”?

- How were the 8 sites selected?

- Clarify the categories (i.e. HCWs were also “vaccine recipients” but I assume you are differentiating? Are there any more demographic characteristics on vaccine recipients? How were they selected?)

- You mention using a theoretical framework—what was the framework used?

- I would make clear from the beginning that vaccine recipients were interviewed through FGDs, HCWs and Key informants through interviews. Maybe you could move Table 1 to the methodology so it’s clearer from the start.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Overall

This paper focuses on the COVID-19 vaccination rollout in Lagos from the perspectives of vaccine recipients, HCWs, and government officers. Overall, the authors do a great job providing and presenting a lot of data on the rollout; I particularly like the inclusion of different perspectives. Some of the language can be cleaned up throughout, but overall, I think it’s a paper the authors should be proud of and is one that will benefit future vaccine rollouts in Nigeria and elsewhere.

Some detailed comments are provided:

Introduction

- Line 80: Provide a little more detail – perhaps the number of vaccines currently produced (can say “at the time of writing”) to provide context of scale

- Lines 80-84: Can you be more specific? Is this clinical data? Consider breaking the sentence into two separate ones for clarity.

- Line 84: were the blood clots discredited, or was it reports that it was unsafe? Please clarify.

- Line 85: Is it possible to be more specific than “Africa”? Maybe “Vaccination against COVID-19 has been slower in countries relying on doses from COVAX than in other places” or something like that.

- Lines 88-89: This is a very important point, but the sentence is unclear. What proportions are you speaking of?

- Line 90: An example of an exemplary rollout would be helpful.

- Lines 91-95: This sentence needs some citation(s), as there have been several reports about why the rollouts/administration may have been delayed – including, but not listed here, countries receiving vaccines right before they were to expire.

- Line 96: Which vaccine was provided?

- Line 106: Did Lagos State receive their share immediately?

- Line 124: When did the vaccine become available to all adults?

- COME BACK TO AIM/LINE 125

Methods

- Overall, the divisions and sub-divisions are a bit unclear. Consider combining some sections or making note of how sub-sections may fit into broader sections (using numbers and/or letters).

- Line 134: Lagos city or Lagos state?

- TOO MUCH INFO? Perhaps link to rollout more and cut the rest… And then connect with study sites

- Lines 158-162: What does it mean to be formally approached? How was that different than approaching vaccine recipients?

- Data collection tools and techniques: I’m a little confused by “qualitative inquiry.” You mean the qualitative data were collected using a guide, correct? Was this guide structured or semi-structured? Please provide a little more detail on the key topics addressed in the guides and how they differed between IDIs and KIIs. Same can be said for the FGDs – please provide a little information on key topics covered.

o Where FGDs held the same day as the recruitment of participants? Or did participants return on a separate day?

- Line 180: The number of IDIs, etc. carried out should be included in the results section. Also, if there were 8 sites and 4 IDIs were carried out at each site, why were 24 conducted (rather than 32)? 24 is still a lot of IDIs, but please comment if there were decliners or a reason why the numbers do not match.

- Lines 183-186: Is there a way to not include their titles? I imagine this makes the KII participants easy to identify… Please be more general in how they are referred to.

- Lines 191-192: Please clarify. “Transcribed verbatim” means word-for-word, so by the rest of the sentence, do you mean that the other notes (e.g. non-verbal cues, etc.) were included into the transcripts as well?

- Line 196: “manuscripts” should be changed to “transcripts”

- Lines 199-207: There is a lot of detail here that I believe can be written/edited in a way that is more succinct and clearer to the reader.

o If no coding software was used, did the authors use Word or Excel?

Results

- The number of KIIs, IDIs, FGDs should be included at the beginning of the results section. Here you can also include some summarized information on the participants (gender, age, etc.)

o Were men and women included in the same FGDs?

o What is the gender breakdown of the IDIs and KIIs?

o I’m still worried that by providing their titles, the identity of the KIIs is easy to figure out.

- Lines 252-254: did the participants themselves have concerns about the government’s motives or the uncertainty of the effect, or was it what they had heard from others? If they had these concerns, what led them to still get vaccinated?

- In this section (myths/misconceptions), it would be helpful to have a specific example or two. Participants seem to have heard of the myths (did they mention any specific myths?) but still got vaccinated. Did anyone say why that was?

o OK, this is mentioned in the next section. Was it the same respondents?

- Liens 303-305: Was this hesitancy the HCWs had seen while working in the clinic – was it directly observed by them? Or was this more of an explanation for wider vaccine hesitancy?

- Lines 308-311: Were participants asked to score the programme during the IDIs? Was this a formal assessment, or was it part of the interview questions? If it was formal, please say more on that and include it in the methods section.

- Line 323: should there be “not” in that sentence?

- Lines 339-351: Since the steps are already mentioned in the intro, I think this section can be cut. Or, the focus should not be on repeating the steps, but on the KII participants’ views on how this went, barriers/successes, etc.

- Section from KIIs in general, lines 331-461: I have a few concerns about this section.

o First, there is a lot of space given to what was only 3 KIIs in comparison to the IDIs and FGDs. Much of the first part is just a summary of the process that occurred, much of which is included in the intro. I think what is most relevant for the study can stay in the intro and then the rest can be removed and instead placed in a figure or text box, possibly to be included in the annex or as supplementary information.

o The parts that bring up the KII participants’ opinions on what went well and what can be improved upon are good and could be elaborated on – especially as their comments relate and compare to what the IDI participants said.

o Lines 423-425: is this the opinion of the participants? As it reads, it sounds almost like they are summarizing a study they did.

o I’m not sure what is different between “barriers” and “challenges.”

- In general, the sub-sections of the Results all follow the same order of plan, process, and progress for each group of participants separately. Something to consider would be blending the results from the different participants so they can be compared and contrasted as it relates to this overall main outline (plan, process, progress). This would keep make the results more succinct, allow for comparison between different groups of respondents, and make the sections and sub-sections easier to follow.

Discussion

- Overall, there is a lot of information in the discussion, but I feel it’s typically very broad and general. I think this section would benefit a lot from clear examples in the literature and how those examples link directly with the data presented in the results.

- Lines 480-481: Sentence needs to be written more clearly.

- Lines 502-507: Are there other reasons why certain sites had better turnout than others? Was it only do to misinformation, or are there structural factors that may play a role?

- Lines 507-508: Citation?

- Lines 513-516: Can you be more specific? Perhaps include more of the information participants gave regarding how or what they want included in vaccine messages and how the rollout may address those issues in the future.

- Lines 517-520: I’m not sure I understand this sentence… How does high morbidity/mortality lead to a reduction in vaccine hesitancy? Also, this is a rather old source – is there anything newer that addresses this issue, particularly as it may relate to COVID?

- Lines 526-531: Is it the AEFIs themselves, or people’s perceptions of the AEFIs that is most important for vaccine uptake?

- Lines 536-541: I find that participants wanted a more bottom-up approach interesting. Was this something that the KII participants discussed too? Is there a way to compare/contrast this desire with the plans of the rollout?

- Lines 542-548: Have there been any studies about incorporating other vaccines into routine immunization?

- Lines 552-556: Can you provide an example of the use of these types of partnerships? How would COVID vaccine rollout be similar or different from these examples? Are there importance lessons that can be applied?

- Overall, how can other countries learn from Nigeria? This study gives details on many challenges and lessons learnt – how can other countries benefit from this information? How can Nigeria benefit from this information in the future?

Reviewer #2: Re: A qualitative analysis of the COVID-19 vaccination rollout in Lagos, Nigeria: Client and

provider perspectives on the plan, the process and the progress

This paper reports on a qualitative study that assessed the plan, process, and progress of the COVID-19 vaccination program in Lagos State Nigeria. Using in-depth interviews and focus group discussions, the authors highlight, from the perspectives of vaccine recipients and healthcare workers, the challenges to the COVID-19 vaccine implementation program in Lagos State including issues around vaccine hesitancy and logistics. Factors that contributed to the success of the program are also presented. The study is novel and has interesting and important findings that could be used to inform future vaccine programs in Lagos and Nigeria generally

The presentation of the paper however needs to be improved in terms of structure, additional information in the Method’s section, and support (quotes from IDIs and FGDs) for some of the key results. My suggestions are as follows:

• Going through the results and certain sections of the abstract, it became less and less clear if the manuscript is reporting on the outcome of research or a monitoring and evaluation exercise. Perhaps this is because of the way the results are presented (especially the choice of words). For example, participants agreed, commending the government of Nigeria, and detailed descriptions of the actual roll out program instead of a presenting the perspectives of the different stakeholder groups without the authors qualifying them as: “genuine” “successful, “unfounded claims” etc. Also, where the authors present the results of IDIs with healthcare workers and key informants, there is an inclination to provide a defence to most of the challenges mentioned by the interviewees. That may be okay, if those reasons are provided in the discussion section for example… although in the interviews, participants mentioned that XXX was a major logistic-related challenge, from our knowledge and experience of the roll out program, this challenge may have been due to XX and was resolved by XX.

• Following up from the point above, it is important for the authors to describe their positionality in the context of this research. For example, where some of them involved in the vaccine roll out program and if so in what capacity and how this may have influenced the results or discussions. This will give researchers some perspectives on the overall narrative and arguments advanced in the paper.

• The methods section needs more information:

• Line 159: vaccine rollout process or vaccine roll out program?

• Line 160: It seems to me like two sampling strategies were used. Purposive (frontline workers) and convenience (clients/vaccine recipients).

• 161: Participants were formally approached- What does this mean? -A description of the process and why that was necessary will provide more clarity

• 164: Delete “For the qualitative inquiry”. The title already states that it is a qualitative study. Also, only qualitative methods were used

• 164: Moderator’s guide: What was the nature of this guide? Semi structured open ended? close ended? What type of questions were included and how was it developed?

• 165: State number of IDIs and KII

• What was the difference between the two? was it in the method or in the stakeholder group interviewed? If methods, then I suggest that should be described. If it is in the stakeholder group, then I suggest you use IDIs across the paper

• The methods section should have a justification of why different methods were used for the different stakeholder groups. For example, why FGDs with vaccine recipients and not IDIs. Similarly, why IDIs with frontline workers and not FGDs. Also, it needs to be stated clearly at the introduction that FGD were conducted with vaccine recipients only and IDIs with healthcare workers and key informants (Administrators?) only. Otherwise, it becomes confusing who was involved in what-especially in the results section.

• How long were the IDIs and KIIs? This information is provided for FGDs but not the other methods.

• How did the authors arrive at the final sample size for each stakeholder group and in the case of FGDs, why 8 participants per FGDs?

• What was the overall study period? When were the FGDs conducted, was it immediately after vaccination? If yes, how were participants selected from the overall pool of persons who presented at the vaccine site on that specific day?

• What was the criteria for selecting the key officers? That is how did the team decide who was a “key informant”? for example why the state epidemiologist and not the Commissioner of Health or the Head of the Nigeria CDC?

• Line 188: Were all the Investigator part of the training or only those responsible for the conducting the FGDs, KIIs etc If not all, consider indicating the initials of those who were trained for this purpose.

• Line 195-196: What does transferability for cultural reasons mean and what impact did this have on the thematic coding and data analysis.

• Line 196: Read the manuscript (transcript?)

• Line 199: A description of the theoretical framework is important to give readers a perspective of the analysis. Is it an existing framework that has been published or used in similar studies or was it developed during the coding process by those involved in the analysis? - If so, was it developed etc. It will also be important to state if the thematic coding was inductive or deductive.

• Line 200: The sentence, “Next, by the process of indexing. This process of indexing needs to be described or referenced for the benefit of your readers.

• Line 203: what is understandable data? Either provide a description or provide a reference of what it means in the context of qualitative research.

• Line 205: Were the several meetings with the four team members involved in the coding or all the authors.

• Line 213: Purely voluntary- I suggest purely be deleted except it goes beyond voluntary.

Results:

• Table 1: Headings in Column 1 are not consistent-In one instance the method is used, in another the name of the stakeholder group. I suggest the authors use 1 across all groups, preferably the stakeholder group (Vaccine Recipients; Front line health care workers etc)

• Overall, the presentation of the results is confusing. It is presented according to the Methods. I suggest the headings should rather be defined by the different Stakeholder Groups. For example, “Perspectives of vaccine recipients on the COVID-19 vaccine rollout Program in Lagos”; “Perspectives of frontline healthcare workers on the COVID-19 vaccine rollout Program in Lagos” etc.

• Line 234: Introduce a quote from the FGDs to support the statement.

• Line 245: The theme needs to be rephrased to capture the goal of the project (COVID-19 vaccine roll in Lagos). For example, “Myths or misconceptions about COVID_19 Vaccine and the impact on the vaccine-roll out program in Lagos State”. The paper is on the vaccine roll out process and not COVId-19 vaccine hesitancy. How it leads to hesitancy can then be capture in the narrative rather than the sub-heading (a key theme)

• Line 249: A supporting quote should be inserted at the end of the sentence “…… conspiracy theories about theCOVID-19 vaccine” to support the analysis/narrative

• Line 249: Sentence starting with Unfounded claims…. I suggest that as much as possible, the authors should remain value neutral in presenting the results and avoid the use of words like “unfounded” except that was used by the participants and there is a supporting quote for that. That phrasing, if necessary, can be used in the discussion section with a supporting argument on why they are considered “unfounded”. I think here is an opportunity by the authors to educate, rather than then dismiss a claim as unfounded” because such dismissals could entrench covid-19 vaccine hesitancy or resistance.

• Line 250: Participants mentioned that..….. Was this all or some, or most of the participants? This applies across the manuscript.

• Line 267. Sentence ending with “achieved faster” needs a supporting quote. Throughout the results, please provide supporting quotes for each result.

• Line The statement “It was also opined that vaccination would help improves the economy…” also requires a supporting quote

• A mentioned earlier, consider replacing In-depth Interviews with a description around the lines “Frontline Workers' Perspectives on COVID-19 Vaccines the roll out program in Lagos Nigeria”

• Why are supporting quotes from the IDIs not reported in the same way as the FGDs? The FGDS for example has the gender and age of the participants in addition to the unique participant number. While the IDIs only have the unique IDs. This needs to be consistent across the paper. Analysis in terms of age and gender are also not presented, so it is hard to tell why the authors reported the FGDs using gender and age.

• Lines 314-318: Up to three quotes are provided to support the results that HCWs commended the government, and all quotes are very similar. I suggest one quote is used for this purpose especially as in most cases, just one quote is provided for a key result- and in other cases no quotes.

• Lines 320- Kindly provide description on the specific aspect(s) of planning that came up from the interviews before providing a quote. One quote should be okay.

• Line 331: Instead of key informant interviews, consider using “Providers Perspectives on COVID-19 Vaccine Roll out in Lagos Nigeria”

• Line 332: Considering the length of this manuscript and readers may have forgotten which stakeholder groups were described as “Providers”, It is important, for the purpose of clarity, to repeat that information in this sentence - May be important to repeat it here for clarity.

• Line 339-351: I suggest the paragraph be deleted as it doesn’t form part of the key results nor adds value to the results. Same for like 357-359.

• Line 367: Please provide a supporting quote.

• Line 370-71: Why was there a need to review the process? I think that is the key information as the article reports on vaccine roll out process.

• Line 386: Issues around logistics has already been reported. Also, Lines 397-407 seems to be an evaluation of the logistics rather than the perspectives of the key informants. I therefore suggest that the paragraph be deleted.

• Lines 442: Please provide supporting quote

• Lines 443: For the entire section, please provide supporting quotes for each of the key results.

• Lines 450-453: It is not clear how failure to observe COVID-19 protocols by the already vaccinated, was a challenge to the vaccine roll out program in Lagos. That will need further explanation.

• Lines 469: the word client has only been introduced in the discussion. My guess is that this refers to vaccine recipients. However, I think, the authors should opt for one description for that stakeholder group and use it throughout the manuscript.

• Overall, the use of “participants” across the results section is confusing, I suggest it should be replaced with the title of each stakeholder group that is being referred to.

• Generally, it is not clear why the results were analysed and presented separately for each stakeholder group? Why was that important and what extra value does it bring to the narrative on COVID-19 vaccine roll out in Lagos. This needs to come out clearly in the introduction and discussion especially as some on the themes are similar across stakeholder groups. If there are no specific reasons, the authors should consider reporting the results by thematic area only and supporting quotes should indicate if it was a HCW, key informant or vaccine recipient

Reviewer #3: This is a very interesting and important article, outlining in great detail the complexities and successes of delivering COVID-19 vaccination in Lagos. I think the article could state its contribution even more strongly, by noting its originality in bringing together perspectives of vaccine recipients and those involved at different levels of the vaccine delivery system. Emphasising the contribution will also require the authors engaging a bit more thoroughly with the social science literature on vaccine confidence and delivery-- the Vaccine Confidence Project can be a good start, and literature by Heidi Larson and colleagues includes some good overviews of the literature.

The area where I think some major revisions are required is in the interpretation of the data. This will not require a great deal of re-analysis, but rather really considering what the data is saying and what it is not. It seemed to me that having interviewed vaccine recipients and providers, the authors cannot in fact suggest to have insight into drivers of vaccine hesitancy. Discussions of conspiracies and mistrust are *reported* by respondents but not in fact stated as reasons for *their* refusal. They are in other words speculations about low uptake. For example on page 20 you state “the poor turnout for vaccination was because awareness was low”— but you haven’t actually explored reasons for refusal/hesitancy with those who refused, so you can only really say that poor turnout was perceived by key informants to be linked to low awareness.

Research has shown that healthcare providers might overstate low awareness when reasons for hesitancy are more complex (see for example Enria et al "Bringing the social into vaccination research" in PLOS One). It does not mean that the fact that providers and vaccine recipients deem this to be significant is not worth stating, but it needs to be interpreted as their speculation rather than as a finding that this is what you take to be the most important issue affecting vaccination uptake. The respondents' description of their encounters of misconceptions in practice are valuable, but need to be interpreted as such, given that they did not in fact drive their own vaccination behaviour (everyone you interviewed is pro vaccination). Is there any data available on uptake in the facilities you studied and the relative significance of supply and demand issues? On page 27 you note “poor uptake”—can this be quantified? Were any access issues reported in your findings? Is there any research you could cite that offers more concrete evidence on the hesitancy problem, if this is indeed a large problem in practice? I thought that it was extremely interesting that your respondents worried there might not be enough vaccines for everyone—how does this relate to concerns about mistrust?

Related to the question of potential hesitancy, I would suggest that you consider a more nuanced interpretation of mistrust in vaccination. There may be more complex reasons why people have low trust in vaccination, and indeed there is very good literature on this from Nigeria as well, which situates for example the polio controversy (see Obadare E. A crisis of trust: history, politics, religion and the polio controversy in Northern Nigeria. Patterns Prejudice. 2005;39(3):265–84.) or broader literature that contestes the “knwoeldge deficit” model (see Goldenberg M. Public Misunderstanding of Science?: Reframing the Problem of Vaccine Hesitancy. Perspect Sci. 2016;24(5):552–81.). You can consider this in the discussion, but as noted above, I would also treat the issue of mistrust much more carefully, with a more nuanced interpretation and perhaps not make it your central finding as I am not sure that is what your data suggests.

Some smaller isses that you could fix:

- Because you are reporting data from very different kinds of respondents, I would make sure that throughout you make clear which you are speaking of—so for example on page 20 instead of saying “most of the respondents”, clarify that this is among key informants

- P.5 why is this study framed as a “risk assessment”?

- How were the 8 sites selected?

- Clarify the categories (i.e. HCWs were also “vaccine recipients” but I assume you are differentiating? Are there any more demographic characteristics on vaccine recipients? How were they selected?)

- You mention using a theoretical framework—what was the framework used?

- I would make clear from the beginning that vaccine recipients were interviewed through FGDs, HCWs and Key informants through interviews. Maybe you could move Table 1 to the methodology so it’s clearer from the start.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Nchangwi Syntia Munung

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0000486.r003

Decision Letter 1

Muhammed O Afolabi

13 Jul 2022

PGPH-D-21-01166R1

A qualitative analysis of the COVID-19 vaccination rollout in Lagos, Nigeria: Client and provider perspectives on the plan, the process and the progress

PLOS Global Public Health

Dear Dr. Kanma-Okafor

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 11 August 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammed Olanrewaju Afolabi, MD, MPH, PhD

Academic Editor

PLOS Global Public Health

Journal Requirements:

1. In the Funding Information you indicated that no funding was received. Please revise the Funding Information field to reflect funding received.

Please ensure that the funders and grant numbers match between the Financial Disclosure field and the Funding Information tab in your submission form. Note that the funders must be provided in the same order in both places as well.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #3: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #3: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Please see attachment

Reviewer #3: Please see uploaded comments

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0000486.r005

Decision Letter 2

Sabine Hermans

12 Oct 2022

A qualitative analysis of the COVID-19 vaccination rollout in Lagos, Nigeria: Client and provider perspectives on the plan, the process and the progress

PGPH-D-21-01166R2

Dear Dr Kanma-Okafor,

Apologies for the delays throughout this editorial and review process, and thank you for submitting your revised manuscript. We are pleased to inform you that your manuscript 'A qualitative analysis of the COVID-19 vaccination rollout in Lagos, Nigeria: Client and provider perspectives on the plan, the process and the progress' has been provisionally accepted for publication in PLOS Global Public Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health.

Best regards,

Sabine Hermans

Academic Editor

PLOS Global Public Health

***********************************************************

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to reviewers.doc

    Attachment

    Submitted filename: Response to reviewers 2 -Aug 2022.doc

    Data Availability Statement

    All the data gathered for this research is available on request but cannot be made publicly available for ethical reasons, to protect the participants’ privacy. The public deposition would breach compliance with the protocol approved by our research ethics board and would compromise participants’ privacy as they would easily be identified. The name of the ethics committee or Institutional Review Board that provided ethical approval for our study is Health Research Ethics Committee, Lagos University Teaching Hospital, Idiaraba, Lagos, Nigeria. A non-author point of contact that is able to receive queries regarding data access is Prof. Oyinkansola Sofola (+234 8033031483, osofola@unilag.edu.ng.


    Articles from PLOS Global Public Health are provided here courtesy of PLOS

    RESOURCES